Analyses from the Cardiotoxicity of Cancer Therapy study showed that BC patients treated with anthracyclines and/or anti-HER2 therapies frequently display subclinical, modest, but persistent indexes of LVD, with only partial recovery over time (26, 27). The gene discussed is ERBB2; the disease is breast cancer.